- Home
- PHK vs GHRS Comparison
PHK vs GHRS Comparison
Compare PHK & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHK
- GHRS
- Stock Information
- Founded
- PHK 2003
- GHRS 2018
- Country
- PHK United States
- GHRS Ireland
- Employees
- PHK N/A
- GHRS N/A
- Industry
- PHK Finance/Investors Services
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- PHK Finance
- GHRS Health Care
- Exchange
- PHK Nasdaq
- GHRS Nasdaq
- Market Cap
- PHK 842.0M
- GHRS 774.1M
- IPO Year
- PHK N/A
- GHRS 2021
- Fundamental
- Price
- PHK $4.86
- GHRS $13.48
- Analyst Decision
- PHK
- GHRS Strong Buy
- Analyst Count
- PHK 0
- GHRS 9
- Target Price
- PHK N/A
- GHRS $29.33
- AVG Volume (30 Days)
- PHK 491.5K
- GHRS 364.5K
- Earning Date
- PHK 01-01-0001
- GHRS 11-13-2025
- Dividend Yield
- PHK 12.61%
- GHRS N/A
- EPS Growth
- PHK N/A
- GHRS N/A
- EPS
- PHK N/A
- GHRS N/A
- Revenue
- PHK N/A
- GHRS N/A
- Revenue This Year
- PHK N/A
- GHRS N/A
- Revenue Next Year
- PHK N/A
- GHRS N/A
- P/E Ratio
- PHK N/A
- GHRS N/A
- Revenue Growth
- PHK N/A
- GHRS N/A
- 52 Week Low
- PHK $4.13
- GHRS $6.72
- 52 Week High
- PHK $5.15
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- PHK 34.04
- GHRS 48.99
- Support Level
- PHK $4.86
- GHRS $12.75
- Resistance Level
- PHK $4.99
- GHRS $14.90
- Average True Range (ATR)
- PHK 0.04
- GHRS 0.83
- MACD
- PHK -0.02
- GHRS 0.03
- Stochastic Oscillator
- PHK 38.35
- GHRS 40.00
About PHK Pimco High Income Fund
PIMCO High Income Fund is a closed-end management investment company. The company's primary investment objective is to seek high current income. Its secondary objective is to seek capital appreciation.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.